McGuff Pharmaceuticals, Inc. Achieves FDA Approval of New Facility
Wednesday, September 25, 2024New Facility Allows for Greater Capacity of Pharmaceutical Manufacturing in the U.S....
Read More
McGuff Pharmaceuticals Inc. announces the Food and Drug Administration’s New Drug Approval of Ascor® Ascorbic Acid Injection, USP
Wednesday, October 18, 2017Ronald McGuff, CEO said "The FDA approval of Ascor® Ascorbic Acid Injection USP will allow McGuff Pharmaceuticals, Inc. to deliver this medically necessary drug to US hospitals and pharmacies to improve patient health. In addition, McGuff Pharmaceuticals, Inc. currently holds Ascorbic Acid Injection USP approvals in multiple other countries."...
Read More
McGuff Pharmaceuticals Inc. (MPI) Has a New Home
Monday, February 27, 2017On behalf of McGuff Pharmaceuticals Inc. (MPI) I am very happy to announce that MPI has signed a lease for 4040 Carriage Drive, Santa Ana CA, 92704. The current tenant will be out of the facility by April and will be under construction for the new facility requirements....
Read More
McGuff Company named one of the top places to work in Orange County for the second year in a row
Thursday, December 10, 2015The McGuff Company is honored to receive the Orange County Register's Top Workplaces of 2015 award. This marks the second year in a row that the McGuff family of companies was recognized....
Read MoreAspen Acquires the Rights to Hydroxyprogesterone Caproate Injection (HPC)
Wednesday, December 02, 2015McGuff Pharmaceuticals, Inc. is pleased to announce that Aspen Global Incorporated ("AGI"), a wholly owned subsidiary of Aspen Holdings, has entered into an agreement with US-based McGuff Pharmaceuticals Inc., a wholly owned subsidiary of McGuff Company, Inc. to acquire the intellectual property and recently...
Read MoreMcGuff Pharmaceuticals, Inc. Announces FDA Approval for Hydroxyprogesterone Caproate Injection, USP (HPC)
Friday, October 02, 2015The FDA has determined MPI’s Hydroxyprogesterone Caproate Injection USP, 250 mg/ mL (1.25 g/5 mL vials) to be bioequivalent and, therefore, therapeutically equivalent to Delalutin Injection, 250 mg/mL formerly produced by Bristol Myers Squibb. MPI’s Hydroxyprogesterone Caproate Injection is the current reference listed drug (RLD) for Hydroxyprogesterone Caproate Injection USP, 250 mg/ mL....
Read MoreCurrent Progress Towards ANDA Approval of Hydroxyprogesterone Caproate Injection, USP
Thursday, June 13, 2013McGuff Pharmaceuticals, Inc. continues to pursue the approval of an Abbreviated New Drug Application (ANDA) for Hydroxyprogesterone Caproate Injection, USP 250mg/mL, 5mL, multiple dose vial; a generic version of Bristol-Myers Squibb's drug formerly known as Delalutin™....
Read More